Premium
The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis
Author(s) -
Sadeghi Narges,
Mansoori Anahita,
Shayesteh Aliakbar,
Hashemi Seyed Jalal
Publication year - 2020
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6581
Subject(s) - curcumin , medicine , ulcerative colitis , erythrocyte sedimentation rate , gastroenterology , placebo , c reactive protein , inflammatory bowel disease , randomized controlled trial , colitis , clinical trial , inflammation , pharmacology , disease , pathology , alternative medicine
Background and aims Curcumin has anti‐inflammatory properties. The aim of this study was to evaluate the effect of curcumin on improvement of the disease activity in ulcerative colitis (UC). Methods In this randomized double‐blind clinical trial, 70 patients with mild‐to‐moderate UC were randomly assigned to curcumin (1,500 mg/day) or placebo intake for 8 weeks. Disease clinical activity, quality of life, serum levels of tumor necrosis factor alpha (TNF‐α), high‐sensitivity C‐reactive protein (hs‐CRP), erythrocyte sedimentation rate (ESR) values, and complete blood count were measured. Results Changes in Simple Clinical Colitis Activity Index score were significantly higher in the curcumin than the placebo group (–5.9 ± 2.08 vs. –2.1 ± 2.6; p = .001). The scores of Inflammatory Bowel Disease Questionnaire‐9 and quality of life were significantly higher in the intervention group compared to the control group ( p = .006). Furthermore, the curcumin supplementation reduced the serum hs‐CRP concentration (–6.3 ± 13.6 vs. 3.7 ± 11.6 μg/ml; p = .01) and ESR levels significantly (–1.6 ± 2.7 vs. –0.09 ± 2.4 mm/hr; p = .02) in comparison with the control group. No significant changes were observed in the TNF‐α levels of both groups. Conclusions Consumption of the curcumin supplement, along with drug therapy, is associated with significant improvement of the clinical outcomes, quality of life, hs‐CRP, and ESR in patients with mild‐to‐moderate UC.